Citi Downgrades MacroGenics (MGNX) to Sell

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Citi Downgrades MacroGenics (MGNX) to Sell

Macrogenics (MGNX) Reports Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab

February 6, 2019 6:00 AM EST

MacroGenics, Inc. (NASDAQ: MGNX) today announced positive results from SOPHIA, the Companys Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients. Margetuximab is an investigational immune-enhancing monoclonal antibody derived from the Companys proprietary Fc Optimization technology platform. The SOPHIA clinical trial met the primary endpoint of prolongation of progression-free survival (PFS) in patients treated with the combination of margetuximab plus chemotherapy compared to trastuzumab plus chemotherapy. Patients in the margetuximab arm experienced a 24% risk reduction in PFS compared to patients in the trastuzumab arm (HR=0.76, p=0.033). Notably, approximately 85% of... More